EU/3/19/2202
About
On 17 October 2019, orphan designation EU/3/19/2202 was granted by the European Commission to Clinical Network Services (NL) B.V., Netherlands, for (16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid (also known as zotiraciclib) for the treatment of glioma.
In August 2020, Clinical Network Services (NL) B.V.changed name to Scendea (NL) B.V.
Key facts
Active substance |
(16E)-14-methyl-20-oxa-5,7,14,26-tetraaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene–citric acid
|
Disease / condition |
Treatment of glioma
|
Date of first decision |
17/10/2019
|
Outcome |
Positive
|
EU designation number |
EU/3/19/2202
|
Sponsor's contact details
Scendea (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: orphan@scendea.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.